Company* (Country; Symbol) | University/ | Type Of | Product Area | Details (Date) |
|
| ||||
3rd Millennium Inc.* | Department | Phase I SBIR contract | To develop a bioinformatics system for the management and analysis of microarray data | The work is supported by the U.S. Army Medical Research and Material Command; the system will advance the DOD's plan in infectious diseases (2/13) |
| ||||
Acambis plc | U.S. government | Contract | To manufacture and deliver 155M doses of smallpox vaccine within the next 12 months | The agreement is worth $428M to Acambis (12/5**) |
| ||||
Aclara BioSciences | Stanford University School of Medicine | Collaboration | To apply Aclara's eTag technology for proteomics research | The Stanford researchers plan to characterize serum autoantibody profiles in a variety of autoimmune diseases to develop immunology proteome panels for use in drug discovery, clinical medicine and academic research (1/17) |
| ||||
Active Pass Pharmaceuticals Inc. (Canada)* | Baylor College of Medicine | Licensing agreement | ABCA4 gene, also known as ABCR, implicated in age-related macular degeneration | Active Pass licensed the rights to the gene (1/3) |
| ||||
Adprotech Ltd. (UK)* | UK Medical Research Council | Licensing agreement | To exploit two MRC patents related to MSP1.19 | The MRC receives an up-front payment, annual fees, milestone payments and royalties on vaccines (1/23) |
| ||||
Agencourt Bioscience | National Institutes | Agreement | For Agencourt to provide genomic services to the NIH's Mammalian Gene Collection project | Agencourt will use its Solid Phase Reversible Immobilization technology to sequence tag mammalian cDNAs as part of the MGC goal to identify and accurately sequence full-length cDNAs (1/22) |
| ||||
AgraQuest | University of California at San Diego | Research agreement | To investigate deep marine sediment microbes for use as biological pest management solutions for controlling fungal disease, insects and nematodes | The research will be carried out in collaboration with the laboratory of William Fenical, from the Scripps Institution of Oceanography, UCSD (2/8) |
| ||||
Albany Molecular Research Inc. | National Cancer Institute | Cooperative research and development agreement | To develop anticancer compounds | AMRI will prepare derivatives of lead compounds to identify new analogues that maintain promising anticancer activity (12/14) |
| ||||
Alfacell Corp. | Martin Michaelis at the Institute of Medicinal Virology at Johann Wolfgang University | Collaboration | Focused on the use of Onconase, an anticancer drug to treat various forms of childhood soft tissue and muscle cancer | Results of in vitro studies show antitumor activity of Onconase against neuroblastoma, rhabdomyosarcoma and chemotherapy-resistant variants of the same cell lines (1/29) |
| ||||
Ambion Inc.* | Massachusetts Institute of Technology | Licensing | For patent applications covering small interfering RNA | Financial details were not disclosed (3/11) |
| ||||
AMDL Inc. | Lung-Ji Chang | Study | To develop a targeted immunogene therapy for breast cancer | The technology will be tested in a breast cancer mouse model (1/9) |
| ||||
American | Russian | Ten-year agreements | To give ABS exclusive rights to distribute in specified markets Russian-manufactured anthrax and smallpox vaccines | One agreement gives ABS the exclusive right to sell and distribute worldwide an anthrax vaccine produced by a Russian manufacturer (1/22) |
| ||||
Amersham | University of Washington | Proteomics collaboration | To integrate protein and messenger RNA expression data | The RNA expression data will be generated using Amersham's Two-Dimensional Differential In-Gel Electrophoresis technology and DNA microarray platform (3/11) |
| ||||
Antex Biologics | Walter Reed Army Institute for Research | Extended product development agreement | To manufacture clinical trial materials | The materials include seed banks and Phase I clinical trial material for the Tracvax vaccine against Chlamydia trachomatis (1/15) |
| ||||
Applied | Vanderbilt | Collaboration | For technologies and applications for proteomics and small-molecule analysis | The parties will use a new direct molecular imaging technique and approach to analyze tissue (2/12) |
| ||||
Applied Genetic | Johns Hopkins | License | For use of adeno- associated virus gene therapy vectors in muscle tissue | AGTC gains the right to develop the AAV technology for injection into human muscle tissue for potential therapy of alpha-1 antitrypsin deficiency and Pompe's disease (2/20) |
| ||||
Atugen AG | University of California at San Francisco | Validation | To validate the function of genetic targets | Atugen USA Inc., a subsidiary of Atugen, will develop GeneBlocs to evaluate in Madin-Darby canine kidney cells genetic targets associated with epithelial membrane regulation; Atugen will get the first option to commercialize resulting technology (1/23) |
| ||||
AVI BioPharma | Oregon State University in Corvallis | Licensing agreement | For a patent titled, “Calcivirus Infections in Humans: Diagnosis and Prevention" | Terms were not disclosed (2/12) |
| ||||
AxCell Biosciences | Marius Sudol of the Mount Sinai School of Medicine | Research collaboration | To research protein interactions in the WW protein domain family, believed to play a role in muscular dystrophy and neurodegenerative diseases, such as Alzheimer's disease | AxCell has an option to negotiate an exclusive, worldwide, royalty-bearing license from the school for peptide targets, gene targets and any other inventions that result (3/11) |
| ||||
AxCell Biosciences | Thomas Jefferson University | Research agreement | For protein interactions associated with an undisclosed gene believed to play a role as a tumor suppressor in multiple cancers | Intellectual property derived from the collaboration will be jointly owned, with AxCell retaining an option to negotiate an exclusive worldwide royalty-bearing license for any joint intellectual property (3/6) |
| ||||
BD Biosciences | Harvard Institute | Collaboration | To generate thousands of gene clones involved in biological processes | Harvard scientists will use the BD Creator gene cloning and expression system to clone the genes; BD Biosciences will retain commercial rights to the resulting cloned genes and will support the proteomics program (1/29) |
| ||||
Bioject Medical | Memorial-Sloan Kettering Cancer Center | Agreement | To study the efficacy of the Biojector 2000 on immune responses to DNA vaccines | The studies will seek to determine the cellular and molecular mechanisms responsible for the enhancement of immunogenicity associated with needle-free injection (1/18) |
| ||||
BioMicro Systems | National Cancer Institute, the Huntsman Cancer Institute and the Buck Institute for Age Research | Agreement | To evaluate its Microarray User Interface hybridization product | The alpha sites will test BioMicro's MAUI microfluid analysis product used to expedite the drug discovery process by obtaining results from microarray hybridization (2/20) |
| ||||
BSKB Medical | California State University, Fullerton | Licensing agreement | To commercialize a technology relating to a new class of potential antibodies | The company formed Pyro Pharmaceuticals Inc. to exploit the technology, which focuses on a metabolic pathway required for bacterial viability (2/6) |
| ||||
Caprion | McGill University | Collaborative agreement | To expand Caprion's proteomics research | Caprion will provide McGill financial support; Caprion will have access to certain intellectual property developed under the collaboration, and will have exclusive rights to license any proteomic technologies developed; the funding could exceed $1M in the next five years (2/27) |
| ||||
Carrington | Southern Research Institute | Partnership | To assist in the commercialization of Carrington's drug delivery technology based on the natural polymer CR1013 | Carrington will retain all product rights plus intellectual property rights to its existing technology, as well as to any discoveries made (1/24) |
| ||||
Celera | Institute for OneWorld Health and the National Institutes of Health | Development agreement | For CRA-3316 as a potential new treatment for Chagas' disease | Celera gave IOWH the exclusive license to develop CRA-3316 for parasitic infections in humans (2/14) |
| ||||
Celera | UK Medical Research Council | Multiyear agreement | For access to Celera's database products | The agreement is open to all UK-based academic researchers (2/1) |
| ||||
Ciphergen | Aaron Diamond AIDS Research Center | Research and license agreement | To pursue projects related to discoveries and samples provided by the center, as well as joint discoveries | Ciphergen retains therapeutic and diagnostic rights to discoveries made under the collaboration, with royalties paid back to Aaron Diamond (2/14) |
| ||||
Ciphergen | Laboratory of Immunoregulation at the National Institute of Allergy and Infectious Diseases | Collaborative research and development agreement | To discover CD8+ T cell-derived antiviral factors | The parties will use Ciphergen's ProteinChip Biomarker System (2/14) |
| ||||
Co.don AG | Massachusetts Institute of Technology and Tufts University | Collaboration | Basic research on tissue engineering | The research is aimed at improving tissue grafts (2/13**) |
| ||||
Collateral | University of Texas Southwestern Medical Center at Dallas | Option | To license exclusive worldwide gene therapy rights | Collateral will evaluate the development and potential commercialization of EPAS1 in its ongoing nonsurgical cardiovascular gene therapy programs (3/13) |
| ||||
Conforma | Duke University Medical Center | Exclusive licensing agreement and research collaboration | Screening technology, X-ray crystal structure information and a proprietary target for drug discovery | Conforma also initiated a research collaboration with a Duke associate professor that gives Conforma a five-year exclusive option to license all inventions that result from the research (12/6) |
| ||||
Cytomyx plc (UK;AIM:CYX) | Papworth | Collaboration | To discover and validate new targets associated with cardiovascular disease | The initial focus will be dilated cardiomyopathy, a disease of the heart muscle; Papworth will receive royalties on products generated through the collaboration (1/16) |
| ||||
Deltagen Inc. | Stanford | Three-year target validation and research collaboration agreement | To develop research projects for jointly selected genes under which Deltagen will provide Stanford nonexclusive access to knockout mice models using its high-throughput technology | Deltagen will have options to obtain exclusive licenses to commercially develop certain inventions developed by Stanford; Deltagen will have rights to use, commercialize and sublicense resulting products (2/19) |
| ||||
DyoDelta | University of | Licensing | For a pharmaceutical compound program developed by the university's John Matsoukas | DyoDelta exclusively licensed DDB-202 for the therapeutic management of multiple sclerosis (3/19) |
| ||||
Endovasc Ltd. Inc. (OTC BB:ENDV) | Stanford | Option | To acquire an exclusive, worldwide patent license for the use of nicotine in stem cell and progenitor cell recruitment focused in the areas of cardiology and neurology | The patent is titled, "Nicotine Receptor Agonists in Stem Cell and Progenitor Cell Recruitment“ (2/4) |
| ||||
Entelos Inc.* | American | Collaboration and research agreement | For drug discovery and development to treat Type II diabetes | The parties will generate novel theories, hypotheses and discoveries relating to Type II diabetes (3/11) |
| ||||
EraGen | McGill | Research | To design universal DNA microarrays using proprietary Aegis technology | The project will produce universal arrays that are not specific to a single organism or set of genes and will allow for simultaneous monitoring of multiple hybridizations (12/5) |
| ||||
Exact Sciences | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University | Collaboration | To develop a novel technology to analyze DNA extracted from stool samples | The technology is known as digital protein truncation (1/30) |
| ||||
Fujirebio | Yale University | Development and commercialization agreement | For cancer diagnostic tests based on the cancer-specific gene Survivin | Fujirebio acquired the rights; agreement also includes diagnostic rights for therapeutic drug monitoring; Fujirebio will provide Yale with license fees, milestone payments and royalties (3/5) |
| ||||
Genentech Inc. | Accelerate Brain Cancer Cure (ABC[2]) | Collaboration | To develop new therapies designed to treat patients with brain cancer | ABC(2) will share development expenses and provide access to its resources; Genentech will design and develop the therapeutics; Genentech will commercialize any resulting products and ABC(2) will receive a royalty on product sales (2/25) |
| ||||
Genome Prairie | Agriculture and Agri-Food Canada research facilities and the National Research Council Plant Biotechnology Institute | Research | To work with wheat and canola, examining the whole plant and studying the crops at the molecular level | The study may lead to the development of plants with improved stress-resistance properties; the research agreement is worth $19.3M (3/1) |
| ||||
GenVec Inc. | National Institutes | Letter contract | To develop and manufacture preventative AIDS vaccines | The agreement could mean up to $10M over three years for GenVec (1/10) |
| ||||
GenVec Inc. | Vaccine Research Center at the National Institute of Allergy and Infectious Diseases | Contract | To use GenVec's adenovector technology to develop and manufacture clinical- grade preventive AIDS vaccine candidates | GenVec also will work on developing an advanced, scaleable vaccine production process using manufacturing technologies developed at GenVec and designed to support product commercialization (2/5) |
| ||||
Hollis-Eden | Uniformed Services University of the Health Sciences and the Henry M. Jackson Foundation for the Advancement of Military Medicine Inc. | Cooperative research and development agreement | To develop HE2100 for use in the area of radiation protection | Hollis-Eden retains all rights to HE2100, including rights to supply it to the U.S. government (2/14) |
| ||||
Hybridon Inc. | Duke University | Collaboration | To develop Hybridon's class of immunomodulatory oligonucleotides | In coordination with the agreement, Hybridon added a senior scientific adviser, David Pisetsky (1/3) |
| ||||
IGEN | U.S. Army Space and Missile Defense Command | Agreement | To sell products to the Army based on IGEN's Origen technology for the detection of specific biological agents | IGEN received and filled an order for 20 Origen analyzers for delivery to the Department of Defense; revenues are expected to be at least $2M (3/13) |
| ||||
Illumina Inc. | Boston University Medical Center | Commercial | To provide single nucleotide polymorphism genotyping services for a large-scale research project on preterm birth | Illumina will use its BeadArray technology to score a set of SNPs thought to be associated with preterm birth (1/29) |
| ||||
Illumina Inc. | Johns Hopkins University, Institute of Genetic Medicine | Commercial | To provide single nucleotide polymorphism genotyping services on a sample collection | Illumina will use its BeadArray technology to determine the frequency of specified SNPs in the sample set; Illumina also will design functional assays for most of the SNP loci provided by the institute (1/9) |
| ||||
Immune Network | Brian Conway of the University of British Columbia | Research | To develop treatment of HIV and hepatitis C virus | The agreement is primarily to learn more about 1F7, an antiidiotypic immunomodulatory monoclonal antibody, as a potential treatment for HIV and HCV (1/22) |
| ||||
InforMax Inc. | State University of New York at Buffalo | License | For the GenoMax enterprise bioinformatics system and Vector NTI Suite | The software solutions will be used to support research activities and provide statwide academic access to InforMax's bioinformatics products (3/6) |
| ||||
Interleukin | University of Arkansas for Medical Sciences, College of Medicine | Collaboration | On the genetic causes of inflammation in relation to Alzheimer's disease and to identify drug targets | Interleukin Genetics will provide gene variations and cell lines while UAMS provides technical knowledge in gene expression and models of Alzheimer's disease (3/4) |
| ||||
Intradigm | University of Maryland at Baltimore | Exclusive access agreement | To patented technologies that include gene delivery polymers and all applications of synthetic vectors to cancer gene therapies that inhibit tumor angiogenesis | Intradigm said it will use the technologies to support its business activities in the discovery and validation of gene function directly in animal models and in development of delivery methods for gene therapies (2/1) |
| ||||
Kourion | Case Western Reserve University | Collaboration | To study the differentiation potential of a type of stem cell obtained by Kourion | A possible application might be the repair and healing of complicated bone fractures; the collaboration is with the university and its researcher, Arnold Caplan (12/20) |
| ||||
Lynx | Dana-Farber Cancer Institute | Collaboration | AIDS research | Parties have the goal of identifying cellular targets for diagnostics and therapeutics for HIV-1 infection (1/3) |
| ||||
Microbiotix Inc.* | Wayne State University and the University of Michigan | Licensing agreement | To a series of antiviral compounds | The compounds discovered through the research efforts of Jiri Zemlicka and John Drach demonstrated activity against a variety of disease-causing viruses, including cytomegalovirus, hepatitis B and Epstein-Barr (12/11) |
| ||||
MitoKor Inc.* | Buck Institute for Age Research and the University of Oregon | Research collaboration and technology transfer and option agreement | To decipher the human mitochondrial proteome | Mitochondrial dysfunction is a major contributing factor in the pathophysiology of major diseases such as Alzheimer's and Parkinson's diseases and Type II diabetes (1/16) |
| ||||
Morewood | Harvard | Nonexclusive license | Morewood's technology for ultra-fast enzymatics | The technology involves a high-throughput screening method of certain molecules for specific biological effects (2/11) |
| ||||
Morphotek Inc.* | The Wistar | Research and development agreement | To develop improved monoclonal antibodies | Morphotek will apply its Morphodoma technology to Wistar Hybridoma cell lines in order to create second- generation hybridomas that produce monoclonal antibodies for the diagnosis and treatment of cancer and other diseases; Wistar and Morphotek will jointly own the second- generation hybridomas (2/6) |
| ||||
Neoprobe Corp. | University of California at San Diego | Exclusive license agreement | For the rights to a compound developed by researchers at UCSD | Lymphoseek is the compound being researched for its effectiveness in identifying lymphatic tissue in breast and melanoma cancer patients (2/4) |
| ||||
Neurogenetics | University of California at Irvine | Research initiative | To research the characterization of a novel target recently linked to Alzheimer's disease | The research is funded in part by a BioStar award (1/28) |
| ||||
NovaRx Corp.* | Hoag Cancer Center | Collaboration | To conduct a Phase II trial using an experimental cancer vaccine in patients with lung cancer | The vaccine is made of nonsmall-cell lung cancer cell lines that have been genetically modified through growth factor-beta antisense (2/4) |
| ||||
Novavax Inc. | Stroke branch of the National Institute of Neurological Disorders and Stroke | Cooperative research and development agreement | E-selectin anti-stroke project | The agreement will test whether repeated administration of low-dose, intranasal E-selectin can induce mucosal tolerance to the protein, causing a shift of immune responses, such that delayed type hypersensitivity is suppressed and the numbers of lymphocytes that produce the anti-inflammatory cytokine is increased (12/19) |
| ||||
Oxford Natural | Center for Research and Development of Ethnomedicinal Plants (Vietnam) | Agreement | For access to a portfolio of plant medicines | The portfolio includes materials with well-documented anticholesterol and hepato-protective functions (1/30**) |
| ||||
Paradigm | Duke University Medical Center | Multiyear collaborative research agreement | To apply metabolomics in drug discovery and development | Paradigm and Duke will research multiple disease areas to identify and validate novel drug targets for drug discovery, as well as discover new biomarkers for use in predictive medicine; cardiovascular disease will be the first project (2/25) |
| ||||
Protein Sciences | National Institute | Contract | The development and production of antigens for new vaccines for HIV/ AIDS | The contract provides for up to $76M in funding through mid-2006 (12/12) |
| ||||
Proteome Systems | Cystic Fibrosis Foundation Therapeutics Inc. | Collaboration | On a proteomics research program to discover protein targets for cystic fibrosis | The proteins may be used to monitor the progression of the disease and lead to more effective intervention strategies, or as potential targets for the development of new drugs (3/19) |
| ||||
Pyrosequencing | University of California at San Francisco | Research | To analyze genes involved in the development and potential progression of multiple sclerosis | Researchers will use Pyrosequencing's PSQ 96 System and analyze the genotypes of about 2,500 patients, their affected siblings and unaffected family members (12/6) |
| ||||
Quatrx Pharma- | Temple | Exclusive worldwide agreement | For an intranasal delivery technology | Quatrx's vitamin D analogue technology platform will be developed for a variety of indications, the first being the topical treatment of psoriasis (1/23) |
| ||||
Quatrx Pharma- | Wisconsin Alumni Research Foundation at the University of Wisconsin and Deltanoid Inc. | Exclusive worldwide development and marketing agreement | For the topical use of vitamin D analogues | No further details were disclosed (1/23) |
| ||||
Rigel Pharma- | Pennsylvania State University and Oklahoma Medical Research Foundation | Agreements for intellectual property | Siclopps technology and the patent estate to the RBX, or ROC1, protein | Rigel in-licensed Siclopps from Penn State; Siclopps will help the company to develop intra-cellular cyclic peptide libraries; Rigel also in-licensed the patent estate from Oklahoma Medical; the protein is a ubiquitin ligase target with potential therapeutic importance in oncology and inflammatory disease (2/21) |
| ||||
Silico Insights | Huntsman Cancer Institute at the University of Utah | Collaboration | To develop a better understanding of cancer mechanisms leading to diagnostic and drug development targets | The agreement will use data resources available at the university to study genealogically related families in clinical settings for the diagnosis and treatment of cancer; the initial focus will be on melanoma (3/11) |
| ||||
SonoLight Pharmaceuticals Corp. (unit of Altachem Pharma Ltd.; Canada; CDNX:AAF) | The Institutes of Chemistry and Biophysics, Acadamia Sinica of Beijing | Exclusive licensing and product development agreement | Technology related to hypocrellins and their derivatives | Financial details were not disclosed (1/8) |
| ||||
Transgenomic | Max Planck Institute for Molecular Genetics | Multiyear collaboration | To develop a high-throughput genetic variation discovery system | The collaboration is funded by the German National Genome Research Network (2/7) |
| ||||
U.S. Genomics | Pui-Yan Kwok, a researcher at Washington University School of Medicine | Research collaboration | Focused on genetics and technology | Kwok's laboratory will employ U.S. Genomics' direct, linear DNA analysis technology for multiple applications; Kwok also will work to extend the development of the technology platform toward additional applications in the field of genetics (2/20) |
| ||||
U.S. Genomics | The Wellcome Trust Sanger Institute | Collaboration | To examine the use of U.S. Genomics' direct, linear DNA analysis technology in research on the human genome | The parties will use the Gene-Engine technology and other aspects of U.S. Genomics' technology platform (1/28) |
| ||||
Xencor Inc.* | California Institute of Technology and Pennsylvania State University | Licensing | To further expand its protein design automation platform | The agreements expand the patent estate of the PDA technology and increase Xencor's computational throughput and accuracy in protein optimization (2/20) |
| ||||
Xencor Inc.* | Johns Hopkins University School of Medicine | Licensing | For U.S. Patent No. 6,190,856 B1 titled, "Methods of Detection Utilizing Modified Bacteriophage“ | The license will expand Xencor's patent estate for its chemical genomics platform, ProCode (3/11) |
| ||||
Xencor Inc.* | Torrey Mesa Research Institute | Discovery | To focus on the discovery of proteins for products in the food, pharmaceutical and personal care industries | Xencor will receive research support, potential milestone payments and royalties on products (1/3) |
| ||||
Xeotron Corp.* | U.S. Navy, Office | Development | To develop technology for a Microfluidic Array Parallel Synthesis System for production of multistrands of oligonucleotides for use in assembling long DNA sequences | The process, based on Xeotron's technology platform, is designed to accelerate production of oligonucleotides with reduced cost; the contract is worth $3M (2/4) |
| ||||
Zetiq | Karolinska | Research | To identify new tumor suppressor genes, which provide protection against unrestricted cell proliferation | Zetiq will use its CamaRx technology platform to screen a large number of putative tumor suppressor genes being studied at the institute (3/19) |
|
| ||||
Notes: | ||||
This chart does not include grant agreements (unless they are also part of a larger collaboration) or agreements between biotech companies and clinical trial centers. | ||||
* Denotes privately held company. | ||||
** Denotes the date the item ran in BioWorld International. | ||||
Unless otherwise noted, shares are traded on the Nasdaq exchange. | ||||
AIM = Alternative Investment Market of the London Stock Exchange; AMEX = American Stock Exchange; CDNX = Canadian Venture Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over the Counter Bulletin Board; SSE = Stockholm Stock Exchange | ||||
